CTSO (CytoSorbents) Dividends per Share : $0.00 (TTM As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Dividends per Share?

CytoSorbents's dividends per share for the three months ended in Jun. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Jun. 2024 was 0.00. As of today, CytoSorbents's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

CytoSorbents Dividends per Share Historical Data

The historical data trend for CytoSorbents's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Dividends per Share Chart

CytoSorbents Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

CytoSorbents Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CytoSorbents's Dividends per Share

For the Medical Devices subindustry, CytoSorbents's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoSorbents's Dividend Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where CytoSorbents's Dividend Yield % falls into.

CytoSorbents Dividends per Share Calculation

Dividends paid to per common share.

CytoSorbents (NAS:CTSO) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

CytoSorbents's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2024 )	/	EPS without NRI (Q: Jun. 2024 )
	=	0	/	-0.07
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

CytoSorbents Dividends per Share Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoSorbents Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

HQE1:Germany

Address

305 College Road East, Princeton, NJ, USA, 08540

Website

https://www.cytosorbents.com

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Executives

Edward Raymond Jones	director	70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch	officer: Chief Financial Officer	3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi	officer: Chief Operating Officer	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan	director, officer: President and CEO	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris	officer: Chief Medical Officer	C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim	director	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel	director	293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator	director	C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico	officer: Chief Financial Officer	10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus	director	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen	officer: Chief Medical Officer	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp	10 percent owner	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley	10 percent owner	9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger	officer: See Remarks	7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino	officer: Chief Financial Officer	C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852